



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai - 400001

IOLCP/CGC/2018
11 August 2018

Subject: Disclosure under Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release

Dear Sir,


Pursuant to Regulations 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Press Release with respect to Financial Results for the Quarter ended 30 June 2018. The same is also available on the website of the Company i.e. www.iolcp.com.

This is for your information & record please.

Thanking You

Yours faithfully,
For IOL Chemicals and Pharmaceuticals Limited

(Krishan Singla) ★
Vice President and Company Secretary



For immediate release

Press Release

IOL Chemicals and Pharmaceuticals Ltd reports strong performance in Q1' FY19 and enhanced annual capacity of flagship product: Ibuprofen by 39%

Ludhiana. 11 August 2018: IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of APIs / bulk drugs and specialty chemicals posted strong performance in the first quarter of financial year 2018-19.

- Net Revenue from operations (QoQ) increased by 68% from ₹ 215 crore to ₹ 362 crore.
- EBIDTA (QoQ) increased to ₹ 43.43 crore from ₹ 27.62 crore showing increase of 57%.
- Net Profit (QoQ) increased by five times to ₹ 14.41 crore from ₹ 2.98 crore
- Exports (QoQ) increased by 88% to ₹ 147 crore .
- Annual capacity of Ibuprofen increased by 39% from 7,200 MT to 10,000 MT.

Mr Vijay Garg, Joint Managing Director said "We are delighted to announce the enhancement of annual capacity of our flagship product: Ibuprofen to 10,000 MT that will result in higher revenue with increased global share and operating margins. The company has also launched various APIs in anti-diabetic, anti-cholesterol and anti-platelets which are getting good response in the market. "

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on Bombay Stock Exchange (Code: 524164) and National Stock Exchange (Code: IOLCP) is one of the leading APIs/ bulk drugs Company, and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories



like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

IOLCP's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene (IBB), Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 10,000 TPA and having backward integrated manufacturing facility at single location. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) was set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including Austria, Belgium, Hungary, Spain, Switzerland, Portugal, Poland, Ireland, USA, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand, Iran etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.

